Amgen Partners With Daiichi-Sankyo For Denosumab In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal includes regulatory milestone payments to Daiichi in exchange for use of Japanese firm’s intellectual property applicable to Amgen’s bone loss therapy.
You may also be interested in...
Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
German firm partners with Amgen on the IND-ready mAb.
Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
German firm partners with Amgen on the IND-ready mAb.
Investors Iron Out AMAG Ferumoxytol Doubts
Shades of MGI’s Aloxi: CMS rule could pay off.